Genomics data from The Cancer Genome Atlas (TCGA) project has led to the comprehensive molecular characterization of multiple cancer types. The large sample numbers in TCGA offer an excellent opportunity to address questions associated with tumo heterogeneity. Exploration of the data by cancer researchers and clinicians is imperative to unearth novel therapeutic/diagnostic biomarkers. Various computational tools have been developed to aid researchers in carrying out specific TCGA data analyses; however there is need for resources to facilitate the study of gene expression variations and survival associations across tumors. Here, we report UALCAN, an easy to use, interactive web-portal to perform to in-depth analyses of TCGA gene expression data. UALCAN uses TCGA level 3 RNA-seq and clinical data from 31 cancer types. The portal's user-friendly features allow to perform: 1) analyze relative expression of a query gene(s) across tumor and normal samples, as well as in various tumor sub-groups based on individual cancer stages, tumor grade, race, body weight or other clinicopathologic features, 2) estimate the effect of gene expression level and clinicopathologic features on patient survival; and 3) identify the top over-and under-expressed (up and down-regulated) genes in individual cancer types. This resource serves as a platform for in silico validation of target genes and for identifying tumor sub-group specific candidate biomarkers. Thus, UALCAN web-portal could be extremely helpful in accelerating cancer research. UALCAN is publicly available at
Introduction
Recent advances in high throughput technologies such as next-generation sequencing (NGS) and microarrays have enabled basic, translational and clinical cancer researchers to investigate molecular changes in DNA, RNA, and proteins at high throughput scale [1] [2] [3] . Using multiple data platforms (including DNA methylation and copy number, and RNA and protein expression), the Cancer Genome Atlas (TCGA) consortium has generated molecular profiles of over ten thousand samples related to multiple cancer types [4] , leading to studies involving the genomic and molecular characterization of individual cancer types [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .
TCGA data provide an opportunity to analyze the associations of various clinicopathologic factors with tumor initiation, progression, and invasion. Publicly available TCGA data ("level 3", i.e. processed data ready for high-level analyses) can be downloaded via web portals such as Genomic Data Commons (https://gdc.cancer.gov/), cBioPortal [25, 26] and firehose Broad Genome Data Analysis Center (https://gdac.broadinstitute.org/). In addition, various R packages such as CGDS-R (https://cran.r-project.org/web/packages/cgdsr/ index.html), TCGA-assembler [27] , and RTCGA Toolbox [28] facilitate programmatic access to TCGA data.
The sheer volume of TCGA cancer genomics data, with its availability in different data formats, makes in-depth analyses difficult for clinicians and cancer researchers who lack bioinformatics/ programming skills. In order to facilitate basic queries of the data, various analytical tools have been developed. One such tool, cBioPortal, allows users to submit sets of genes for a cancer type of interest. For each gene queried, cBioPortal provides RNA level expression data, mutation events, copy number alterations, protein expression by Reverse Phase Protein Array (RPPA), a survival plot, and a list of co-expressed and mutually expressed genes. Other tools such as miRGator v3.0 [29] , TANRIC [30] , and ISOexpresso [31] can be used to analyze differential expression of specific biomolecules such as miRNA, lincRNA, and transcript isoforms, respectively. Gene-Drug Interaction for Survival in Cancer (GDISC) web portal [32] aids in estimating the effect of gene-drug interactions on various cancer types using TCGA data. The Cancer Genome Atlas Clinical Explorer (Stanford-TCGA-CE) [33] aids in finding associations between genomic/proteomic features and clinical parameters, hence finding potentially clinically relevant genes. PROGgeneV2 facilitates comprehensive survival analysis of publicly available gene expression data including TCGA [34] . Oncomine [35, 36] provides an interactive platform for gene expression profiling, using TCGA and other published cDNA, Affymetrix, and Illumina microarray data.
While the web resources noted above are highly useful for a multitude of data analyses, there is a need for a tool that allows cancer researchers to perform the following: 1) compare gene expression between specific subsets as defined within each cancer type, e.g. subsets based on pathological stages or tumor grade, patient gender, patient race, patient drinking or smoking history, or molecular subclasses; and 2) examine associations between gene expression and various clinical parameters (e.g. patient's race). As heterogeneity existing within a given cancer type has been recognized as an important factor influencing the patient outcome [37] , subgroup analyses can lead to a better understanding of a given disease.
For example, using existing tools, one can readily analyze the expression level of a given gene in primary breast invasive carcinoma (BRCA) as compared to non-cancer ("normal") samples, but one may also want the ability (not easily facilitated by existing tools) to carry out additional analyses, which might include: 1) surveying the differential expression of a gene in luminal, HER2 positive, or triple negative breast cancer, 2) testing whether post menopause breast cancer patients show higher expression than pre-menopause patients for a given gene, 3) testing whether African American breast cancer patients show higher expression than Caucasian patients for a given gene, 4) testing whether a given gene shows similar expression in patients across age groups, and 5) analyzing the impact of high expression of a given gene on overall patient survival, in either African American or Caucasian patients. In addition, UALCAN provide critical information and graphic ability to make stage, grade, race and other sub status specific expression features from transcriptome sequencing data some of which are unique to this web portal. The UALCAN data portal can aid in the identification of candidate biomarkers of specific cancer subclasses, with diagnostic, prognostic or therapeutic implications. It can also be used as a platform for in silico validation of target genes. UALCAN transcriptome data analysis tools help make TCGA data and analysis results more accessible to a larger group of cancer researchers.
Methods

Data Collection
TCGA-Assembler [27] , was used to download TCGA level 3 RNA-seq data related to 31 cancer types. It was installed on R 3.2.2 (https://cran.r-project.org/). Using TCGA assembler "rsem.genes. results" files were obtained for 'Primary Solid Tumor' and 'Solid Tissue Normal' for each cancer. The "rsem.genes.results" file includes gene expression values estimated by RSEM algorithm for 20,502 genes; the "raw_count" column shows the number of unfiltered fragments that are aligned with gene, and the "scaled_estimate" column provides estimation of transcripts generated from the gene. As described by Li and Dewey [40] , the "scaled_estimate" was multiplied by 10 6 to obtain transcripts per million (TPM) expression value using in-house PERL (Practical Extraction and Report Language) program. We used TPM as the measure of expression, as it has been suggested to be more comparable across samples than FPKM (Fragments Per Kilobase of transcript per Million mapped reads) and RPKM (Reads Per Kilobase of transcript per Million mapped reads) [41] .
In addition to gene expression data, patient data was obtained for all cancers from Genomic Data commons (GDC) (https://gdc.cancer.gov/) using GDC data transfer tool. The downloaded data included clinical parameters such as age, sex, race, survival status, tumor grade, tumor stage and so on, for each patient in the XML (eXtensible Markup Language) file. A PERL script was written to parse all XML files corresponding to specific cancer and extract them into a tab separated file.
Data Analyses
The gene expression and clinical patient data were downloaded from TCGA and processed to generate three major types of graphical outputs, described as follows: information, then body mass index (BMI) was calculated using the below mentioned formula (http://www. epic4health.com/bmiformula.html) BMI = (weight in kilograms)/((height in meters) × (height in meters)) Using BMI values, patients were categorized into four groups. Patients with BMI ranging from 18 to 24 were classified as "normal weight", those with BMI ranging from 25 to 29 were classified as "extreme weight", those with BMI ranging from 30 to 39 were classified as "obese" and patients with BMI equal or above 40 as "extreme obese" (https://www.nhlbi.nih.gov/health/ educational/lose_wt/BMI/bmi_tbl.pdf). g) Smoking status: where smoking status information was available, samples were categorized into four groups including smoker, non-smoker, reformed smoker1 (who are current reformed smokers for b= 15 years), and reformed smoker2 (who are current reformed smokers for N15 years). h) Drinking habit: Based on information availability, samples were categorized into groups such as daily drinker, weekly drinker, social drinker, occasional drinker, and non-drinker. i) Menopause status: Patient data corresponding to breast cancer and endometrial carcinoma includes menopause status, with samples categorized as "pre-menopause", "peri-menopause" and "post-menopause". j) Molecular signature: In case of prostate adenocarcinoma, 246 primary prostate tumor samples were divided into seven subtypes defined by ERG (ETS transcription factor), ETV1/ 4 (ETS variant 1/4) and FLI1 (Fli-1 proto-oncogene, ETS transcription factor) gene fusions and SPOP (speckle type BTB/POZ protein), FOXA1 (forkhead box A1) and IDH1 (isocitrate dehydrogenase (NADP(+)) 1, cytosolic) mutations [17] . Similarly, primary breast cancer samples were divided into luminal, HER2 positive, and triple negative subclasses based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status by immunohistochemistry (IHC). In addition 116 triple negative breast cancer samples were categorized into six TNBC subtypes (such as basal-like1 or BL1, basal-like2 or BL2, immunomodulatory or IM, mesenchymal or M, mesenchymal stem-like or MSL, and luminal androgen receptor or LAR) using TNBCtypes tool [42, 43] . TPM values employed for the generation of boxplots were also used to estimate the significance of difference in gene expression levels between groups. The Kaplan-Meier survival plot was generated for every gene in each TCGA cancer type, using "survival" package [44] and "survminer" package [45] . The survival curves of samples with high gene expression and low/medium gene expression were compared by log rank test. In order to assess the combined survival effect of gene expression and clinical parameters such as patient race, gender, BMI, cancer subtypes, tumor grade, etc., we applied multivariate KaplanMeier survival analysis [46] . For example, to estimate combined effect of the expression level of a given gene and racial disparity on breast cancer patient survival, the samples were first divided into two groups: samples with high expression of the gene and samples with low/medium expression. Then, within each expression category, patients were further stratified into three subgroups based on race (African American, Caucasian, Asian). R scripts were written to divide all patients into these six categories and to generate Kaplan-Meier plot. The P value obtained from log-rank test was used to indicate statistical significance of survival correlation between groups. Such multivariate survival analyses were performed for all genes within each TCGA cancer type. The plots were also generated in SVG and PDF formats.
Results
Usage of UALCAN
UALCAN is hosted on CentOS server with 72 cores (Intel ® Xeon® CPU E2-2699 v3 @2.30GHz), 98 GB RAM, and 22 TB HDD. The interface was developed using PERL-CGI, while CSS and javascripts were utilized to implement user-friendly features.
The analysis page of the UALCAN includes three panels (Figure 1 ). The left side panel on analysis page shows a list of cancer types, which are hyperlinked to a web page showing heatmaps of top differentially expressed genes (Figure 2 ). The top 250 over-and under-expressed genes are shown separately for those cancer types with data on N10 Neoplasia each gene can be obtained by clicking on the gene name. Glypican 3 (GPC3), Lipocalin 2 (LCN2), Secreted phosphoprotein 1 (SPP1), and ubiquitin conjugating enzyme E2 C (UBE2C) are listed as top four over-expressed genes. Careful observation reveals that expression profile of LCN2 and SPP1 in liver hepatocellular carcinoma show no significant change across patients of different race, GPC3 shows significantly higher expression in Asian patients compared to Caucasian patients, and UBE2C shows significantly higher expression in Asian patients compared to both African American and Caucasian patients. The schematic representation of this analysis is provided in Supplementary Figure 1 [48] . Therefore, identification of biomarkers specific to breast cancer subtype can be considered extremely important. In UALCAN, TCGA BRCA tumors can be subdivided into "luminal," "HER2 positive," and "TNBC" groups, with the levels of a given gene being shown across these groups. Starting with the expression profile of the top 25 over-expressed genes in breast cancer (as shown in the associated heatmap), one can observe, for example, that both Baculoviral IAP repeat containing 5 (BIRC5) and Ubiquitin conjugating enzyme E2 C (UBE2C) show higher expression in TNBC samples compared to other tumor samples. Using UALCAN, the expression patterns of BIRC5 and UBE2C across molecular subtypes of TNBC can also be explored (Supplementary Figure 5) .
Discussion
The molecular profiling data generated by TCGA consortium has great value in increasing our understanding of the underlying molecular mechanisms involved in various cancers, as well as in the identification of novel therapeutic and diagnostic biomarkers [49] [50] [51] [52] . In order to maximize TCGA data as a community resource, it is important to provide web resources that allow cancer researchers and clinicians (regardless of their levels of computational expertise) to access, analyze, visualize, and interpret the data with ease. For example, one of the possible ways to prioritize genes for further study, in terms of their potential oncogenic or tumor suppressor properties, is to identify genes with expression associated with patient survival. The user friendly interface of UALCAN facilitates the identification of survival associations involving any gene of interest, across different cancer types as well as cancer subtypes as defined by various clinicopathologic features. Multiple public resources such as cBioPortal [25, 26] , miRGator v 3.0 [29] , TANRIC [30] , and ISOexpresso [31] aid in the comprehensive analysis of transcriptomic TCGA data. While cBioPortal, for example, is extremely useful in exploring gene-level associations across different cancers involving mutation frequency or gene expression, there remains a need for tools allowing one to examine RNA level expression differences or survival associations across different cancer subsets as defined by clinicopathologic features. In future, we will incorporate additional transcriptome sequencing datasets from various cancers as well as additional utilities like co-expression analysis, long non-coding RNA analysis and microRNA analysis from the available datasets. We believe that UALCAN can greatly aid cancer biologists and clinicians in the identification of novel diagnostic and therapeutic targets, investigate the gene expression and its disease association in any particular cancer. With its intuitive features, UALCAN will enable researchers across disciplines to easily query for the target or gene of their interest in cancer and make cross-disease associations.
